{
    "nct_id": "NCT05090566",
    "official_title": "A PHASE 1B/2, OPEN LABEL UMBRELLA STUDY OF ELRANATAMAB (PF-06863135), A B-CELL MATURATION ANTIGEN (BCMA) CD3 BISPECIFIC ANTIBODY, IN COMBINATION WITH OTHER ANTI-CANCER TREATMENTS IN PARTICIPANTS WITH MULTIPLE MYELOMA",
    "inclusion_criteria": "* Relapsed/refractory multiple myeloma with at least 3 prior lines of therapy\n* Refractory to at least one IMiD, one proteasome inhibitor, and one anti-CD38 antibody\n* Measurable disease defined by at least one of the following:\n\n  1. Serum M-protein >/= 0.5 g/dL by SPEP\n  2. Urinary M-protein excretion >/= 200 mg/24 hours by UPEP\n  3. Serum immunoglobulin FLC >/= 10 mg/dL (>/= 100 mg/L) AND abnormal serum immunoglobulin kappa to lambda FLC ratio\n* ECOG performance status 0 -1\n* Resolved acute effects of any prior therapy to baseline severity or CTCAE Grade </= 1\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Active plasma cell leukemia\n* Amyloidosis\n* Stem cell transplant with 12 weeks prior to enrollment, or active GVHD\n* POEMS syndrome\n* Any active uncontrolled bacterial, fungal, or viral infection\n* Impaired cardiovascular function or clinically significant cardiovascular diseases within 6 months prior to enrollment\n* Previous administration with an investigational drug within 30 days or 5 half-lives preceding the first dose of study treatment (whichever is longer)\n* Sub-Study A Only: Previous treatment with BCMA bispecific antibody\n* Sub-Study B Only: Previous treatment with BCMA directed therapy",
    "miscellaneous_criteria": ""
}